Condition: Autism Spectrum Disorder · Sponsor: New York State Psychiatric Institute
This Phase 2 study examines the safety, tolerability, and preliminary efficacy of pimavanserin in individuals with Autism Spectrum Disorder. Male or female participants aged 12 to 40 years of age will be randomized to receive single doses of either placebo or pimavanserin in this randomized, placebo-controlled, cross-over designed study, followed by open label extension.
This description comes directly from the study's public registry record.
Alyssa Verdes, BA · 914-997-5532 · alyssa.verdes@nyspi.columbia.edu
Suvekcha Bhattachan, MA · 914-997-5587 · suvekcha.bhattachan@nyspi.columbia.edu
Always discuss trial participation with your own doctor first.
| University of Kansas, Center for Research | Lawrence, Kansas, United States | Recruiting |
| Center for Autism and the Developing Brain | White Plains, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05999240